Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
33 Parkinson Disease Trials near Los Angeles, CA
Power is an online platform that helps thousands of Parkinson Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerTavapadon for Parkinson's Disease
Los Angeles, CaliforniaThis trial is testing a medication called tavapadon to see if it is safe and effective for people with Parkinson's Disease. The medication aims to help manage symptoms like tremors and stiffness by targeting specific parts of the brain.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40 - 80
Sex:All
992 Participants Needed
ABBV-951 Infusion for Parkinson's Disease
Los Angeles, CaliforniaParkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how safe and effective ABBV-951 is in adult participants with PD. Adverse events and change in disease activity is evaluated.
ABBV-951 is an investigational (unapproved) drug containing Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP) given as an infusion under the skin for the treatment of Parkinson's Disease. Adult participants with advanced PD and who have completed M15-736 or M20-339 study will be enrolled. Approximately 130 participants will be enrolled in the study in approximately 60 sites in the United States and Australia.
Participants will receive continuous subcutaneous infusion (CSCI) (under the skin) of ABBV-951 for 96 weeks during the Primary Treatment Period and during the optional Extended Treatment Period.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical and remote telephone assessments, blood tests, checking for side effects, and completing questionnaires.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:30+
Sex:All
118 Participants Needed
BIA 28-6156 for Parkinson's Disease
Los Angeles, CaliforniaThis trial is testing a new drug called BIA 28-6156 to see if it can slow down movement problems in people with Parkinson's disease who have a specific genetic mutation. The study will compare the drug to another treatment over a period of several months.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:35 - 80
Sex:All
237 Participants Needed
Prasinezumab for Early Parkinson's Disease
Los Angeles, CaliforniaThis multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of three parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2). Participants who complete Part 2 (including the 12-week treatment-free follow up visit assessing long term safety and efficacy of RO7046015) will be offered participation in Part 3 open-label extension (all-participants-on-RO7046015-treatment) for an additional 260 weeks.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40 - 80
Sex:All
316 Participants Needed
ANPD001 for Parkinson's Disease
Los Angeles, CaliforniaThis clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 1
Age:50 - 70
Sex:All
9 Participants Needed
Brain Stimulation for Parkinson's Disease
Los Angeles, CaliforniaThis trial is testing whether changing the way the brain is stimulated can improve thinking and movement in people with Parkinson's Disease who already have a brain stimulator. It compares a new type of stimulation (theta burst) with the usual type (gamma). The goal is to see if different electrical impulses can make a difference in brain function. Theta burst stimulation has shown promise in improving motor behavior and synaptic plasticity in experimental parkinsonism.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Epilepsy, Dementia, Substance Abuse
32 Participants Needed
High-density Microelectrode for Parkinson's Disease
Los Angeles, CaliforniaThe purpose of this study is to test the ability of a newly-designed electrode to measure the activity of individual nerve cells (neurons), and collections of nerve cells (local field potentials) in the brain. The study's main goals are to see how well this electrode works compared to standard electrodes and to validate its safety.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:18+
Sex:All
10 Participants Needed
UCB0022 for Parkinson's Disease
Los Angeles, CaliforniaThis trial is testing UCB0022, a new medication, to see if it can help people with advanced Parkinson's Disease. It is added to their regular treatments to see if it reduces the time they spend with bad symptoms. The goal is to make their usual treatments work better.
Stay on current meds
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:35 - 85
Sex:All
207 Participants Needed
Minzasolmin for Parkinson's Disease
Los Angeles, CaliforniaThe purpose of the study is to estimate the pharmacodynamic effects of minzasolmin (UCB0599) on brain pathophysiology in Early-start versus Delayed-start participants originally diagnosed with new onset Parkinson's disease.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40 - 78
Sex:All
428 Participants Needed
Long-Term Treatment for Parkinson's Disease
Los Angeles, CaliforniaThis study seeks to establish the safety and efficacy of extended twice daily treatments for treating symptoms associated with PD. Only participants who completed the STEM-PD RCT trial are eligible for the OLE.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Age:18 - 85
Sex:All
220 Participants Needed
Zoledronic Acid for Parkinson's Disease
Los Angeles, CaliforniaThis home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 2650 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:60+
Sex:All
2650 Participants Needed
Carvedilol for Parkinson's Disease
Los Angeles, CaliforniaThe purpose of this study is to investigate the long-term effects of treatment with the adrenergic blocker carvedilol on serial DaTscan, a dopamine transporter (DAT) single photon emission computerized tomography (SPECT) imaging technique in a population of subjects with defined pre-motor Parkinson's disease risks (i.e., REM sleep Behavior Disorder (RBD) and at least one among hyposmia, constipation, depression and color vision abnormality) and abnormal 123I-Metaiodobenzylguanidine (MIBG) scintigraphy.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:18 - 85
Sex:All
15 Participants Needed
Suvecaltamide for Tremors in Parkinson's Disease
Los Angeles, CaliforniaThis trial tests suvecaltamide, a medication aimed at reducing severe tremors in adults with Parkinson's disease whose current treatments are not effective. The medication likely helps by calming the overactive nerves or muscles responsible for the tremors.
Trial Details
Trial Status:Recruiting
Age:40 - 85
Sex:All
160 Participants Needed
ND0612 for Parkinson's Disease
Los Angeles, CaliforniaThis is a multi-center, randomized, double-blind, double-dummy, active controlled clinical Study. Following a screening period, eligible subjects will be enrolled to an open-label oral IR-LD/CD adjustment period; then an open-label ND0612 conversion period; then after optimization periods subjects will be randomized to receive either ND0612 or its matching Placebo with IR-LD/CD.
Subjects can continue to an optional open-label extension period.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:30 - 80
Sex:All
381 Participants Needed
BIIB122 for Early-Stage Parkinson's Disease
Los Angeles, CaliforniaThis trial is testing a new drug called BIIB122 to see if it can slow down symptoms in people with early-stage Parkinson's disease. The drug works by blocking a protein that may cause the disease to get worse. Participants will take the drug for several years to see if it helps.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:30 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Stroke, Dementia, Seizure, Others
640 Participants Needed
KM-819 for Parkinson's Disease
Glendale, CaliforniaThis trial is testing KM-819, a new drug, to see if it can stop or slow down Parkinson's disease. It involves healthy older adults and people with Parkinson's disease. Researchers aim to find out if KM-819 is safe and can improve symptoms and daily function in these patients.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40+
Sex:All
314 Participants Needed
CereGate Therapy for Freezing of Gait in PD
Los Angeles, CaliforniaA Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:21 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Seizures, Drug Abuse, Advanced Parkinson's, Others
Must Be Taking:Carbidopa/Levodopa, Dopamine Agonists
41 Participants Needed
Non-invasive Brain Mapping for Parkinson's Disease
Los Angeles, CaliforniaSeveral strategies or contexts help patients with Parkinson's disease to move more quickly or normally, however the brain mechanisms underlying these phenomena are poorly understood. The proposed studies use complimentary brain mapping techniques to understand the brain mechanisms supporting improved movements elicited by external cues. The central hypothesis is that distinct networks are involved in movement improvement depending on characteristics of the facilitating stimulus. Participants will perform movement tasks during recording of brain activity with EEG and MRI. The identified biomarkers may provide targets for future neuromodulation therapies to improve symptoms that are refractory to current treatments, such as freezing of gait.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Dementia, Hallucinations, Psychosis, MRI Contraindications
90 Participants Needed
Movement Task Facilitation for Parkinson's Disease
Los Angeles, CaliforniaSeveral strategies or contexts help patients with Parkinson's disease to move more quickly or normally, however the brain mechanisms underlying these phenomena are poorly understood. The proposed studies use intraoperative recordings during DBS surgery for Parkinson's disease to understand the brain mechanisms supporting improved movements elicited by external cues. The central hypothesis is that distinct networks are involved in movement improvement depending on characteristics of the facilitating stimulus. Participants will perform movement tasks during awake surgery performed exclusively for clinical indications. The identified biomarkers may provide targets for future neuromodulation therapies to improve symptoms that are refractory to current treatments, such as freezing of gait.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cognitive Disease, Psychiatric Disease, Others
Must Not Be Taking:Anticoagulants, Antiplatelets
40 Participants Needed
Terazosin Therapy for Parkinson's Disease
Los Angeles, CaliforniaThis trial is testing terazosin, a medication that helps relax muscles and improve blood flow, on people with early signs of Parkinson's disease risks. The goal is to see if it can slow down or prevent the progression of the disease. Terazosin and similar drugs were recently found to enhance energy production and reduce Parkinson's disease progression in animal studies and human data.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Dementia, Severe Depression, Hypertension, Diabetes, Others
Must Not Be Taking:Beta-blockers, Phosphodiesterase Inhibitors
15 Participants Needed
Terazosin for Early Parkinson's Disease
Los Angeles, CaliforniaParkinson's disease (PD) is characterized by many non-motor symptoms that occur several years before the diagnosis, in particular idiopathic REM behavior disorder (iRBD), which is associated with autonomic impairment. The purpose of this study is to investigate the effect of treatment with the selective post-synaptic a1-adrenergic blocker terazosin on 123I-MIBG myocardial uptake in a population of subjects with defined pre-motor PD risks (i.e. hyposmia and RBD) and abnormal baseline 123I-MIBG uptake, with or without 123I-Ioflupane uptake abnormality or PD motor symptoms. Scintigraphic changes will be correlated to motor and non-motor severity of PD, measured by validated clinical scales and cardiac autonomic function tests.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Dementia, Severe Depression, Hypertension, Diabetes, Others
Must Not Be Taking:Alpha Blockers, PDE5 Inhibitors
15 Participants Needed
Carvedilol for Early Parkinson's Disease
Los Angeles, CaliforniaREM Behavior Sleep Disorder (RBD) is a sleep disorder causing people to 'act out' their dreams. A high percentage of individuals with idiopathic RBD (iRBD) are known to develop conditions affecting the neurons in the brain such as Parkinson's disease (PD). Based on the increased risk to develop PD, individuals with iRBD are currently considered ideal candidates for therapies that can possibly protects brain cells, due to the critical window of opportunity to intervene early before brain cell loss progresses significantly.
Early changes of PD are associated with a number of symptoms including loss of smell, constipation, anxiety and depression. In addition, early heart and brain abnormalities can be visualized using specialized imaging techniques called 123I-MIBG myocardial scintigraphy (MIBG) and dopamine transporter (DAT) single photon emission computerized tomography (SPECT) respectively. The combined presence of certain symptoms and the use of these imaging techniques are considered early markers of PD in individuals with iRBD.
In other conditions, like heart failure, MIBG abnormalities are reversed by drugs able to block excessive adrenergic stimulation, known as beta-blockers. In this study the investigators want to learn about the effect of treatment with the beta-blocker carvedilol on MIBG abnormalities found in iRBD patients at risk to develop PD. The investigators believe that reversing the MIBG abnormality might prelude to a slowing of the neurodegenerative process. This drug is approved by the U.S. Food and Drug Administration (FDA) for congestive heart failure, hypertension and left ventricular dysfunction after myocardial infarction. However, carvedilol is not approved by the FDA in patients with iRBD at risk for PD. The available doses for this drug oral formulations are 3.125mg, 6.25mg, 12.5mg and 25mg.
Changes visualized with the MIBG imaging technique will be correlated to the presence and severity of neurological (i.e. tremors, stiffness, slow movements, walking difficulties) and other symptoms associated with PD (i.e. abnormal smell, constipation, depression, color vision abnormalities), as measured by specific clinical scales and exams.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 85
Sex:All
15 Participants Needed
Transcranial Focused Ultrasound for Dementia
Santa Monica, CaliforniaThis trial is testing a treatment that uses sound waves aimed at specific brain areas to help patients with memory and cognitive issues. The goal is to see if this method is safe and effective for people with mild cognitive impairment or dementia. The therapy has been shown to be effective and safe in animal models of Alzheimer's disease and vascular dementia, with previous trials indicating a tendency to suppress cognitive impairment.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Age:45 - 93
Sex:All
100 Participants Needed
IkT-148009 for Parkinson's Disease
Reseda, CaliforniaThis trial tests the safety and effects of IkT-148009, a daily pill, in people aged 30 to 80 with untreated Parkinson's disease. The drug aims to block an enzyme that may help manage symptoms. Participants will take the drug for a few months.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:30 - 80
Sex:All
120 Participants Needed
Lenrispodun for Parkinson's Disease
Reseda, CaliforniaThis trial is testing a medication called Lenrispodun to help people with Parkinson's Disease. It aims to reduce symptoms that appear when their usual medication stops working and to control involuntary movements caused by their current treatment. The study involves an initial check-up, a phase where patients receive either Lenrispodun or another substance, and a later check-up to ensure safety.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Late-stage PD, Dementia, Others
Must Be Taking:Levodopa, MAO-B Inhibitors
132 Participants Needed
Lu AF28996 for Parkinson's Disease
Los Alamitos, CaliforniaThis trial is testing a new drug called Lu AF28996 to see if it is safe and well-tolerated in people with Parkinson's disease. The study will check how the body processes the drug and if it causes any side effects. Participants will take the drug at different frequencies during the study.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:35 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Neurological, Psychiatric, Seizure, Respiratory, Others
Must Be Taking:Levodopa
63 Participants Needed
LY4006896 for Parkinson's Disease
Los Alamitos, CaliforniaThe purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:40 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Neurological Disease, Unstable Illnesses, Allergies, Others
Must Be Taking:Dopaminergic Therapy
127 Participants Needed
VENT-02 for Parkinson's Disease
West Hills, CaliforniaThis trial is a randomized, double-blind, placebo-controlled Phase 1b study evaluating the safety/tolerability, PK, and pharmacodynamics of VENT 02, administered orally at 1 dose level twice daily (BID) over 28 days in patients with mild to moderate Parkinson's disease.
The study includes a screening period, a 28-day double-blind treatment period, and a 7-day follow-up period after last dose.
Approximately 30 patients will be randomized into 1 of the 2 treatment arms.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:45 - 90
Sex:All
Key Eligibility Criteria
Disqualifiers:Hepatitis, HIV, Dementias, Epilepsy, Others
Must Not Be Taking:Anticoagulants
30 Participants Needed
Continuous Subcutaneous Infusion of Levodopa/Carbidopa for Parkinson's Disease
Fountain Valley, CaliforniaThis trial tests a pump that delivers medication under the skin for patients with advanced Parkinson's Disease. The treatment aims to improve movement symptoms by increasing dopamine levels in the brain. This method has been used for many years to manage motor complications in advanced Parkinson's Disease.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:30+
Sex:All
214 Participants Needed
Gene Transfer for Pompe Disease
Orange, CaliforniaThis trial is testing a new treatment called SPK-3006 for adults with late-onset Pompe disease who are already on enzyme replacement therapy. The treatment involves an infusion that delivers a gene to help produce a missing enzyme. The goal is to see if this new approach is safe and effective.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
4 Participants Needed
Page 1 of 2+
Learn More About Power
My name is Bask, and I helped to start the company here. We started Power when my Dad was diagnosed with multiple myeloma, and I needed a better way to understand how he could access the most promising immunotherapy for his illness.
Bask GillCEO at Power
Frequently Asked Questions
How much do Parkinson Disease clinical trials in Los Angeles, CA pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Parkinson Disease clinical trials in Los Angeles, CA work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Parkinson Disease trials in Los Angeles, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Los Angeles, CA for Parkinson Disease is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Los Angeles, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Parkinson Disease medical study in Los Angeles, CA ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Parkinson Disease clinical trials in Los Angeles, CA ?
Most recently, we added High-density Microelectrode for Parkinson's Disease, TB006 for Parkinson's Disease and VENT-02 for Parkinson's Disease to the Power online platform.